All In Biotech

Drug Trial Radar · NCT00613938

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Tapentadol Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy

Last checked: Nov 19, 2026Latest source record: May 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 901 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

901

Actual

Start

Feb 2008

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Grünenthal GmbH
First posted
Feb 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of 2 different dose levels of tapentadol (CG5503) compared with oxycodone and with placebo in subjects who have had a bunionectomy.

Conditions

  • Arthralgia
  • Bunion
  • Hallux Valgus
  • Pain

Interventions

  • Tapentadol (CG5503)Drug

    50mg capsule q4-6 hrs for 3 days

  • Tapentadol (CG5503)Drug

    75mg capsule q4-6 hrs for 3 days

  • oxycodoneDrug

    10mg capsule q4-6 hrs for 3 days

  • placeboDrug

    1 capsule q4-6 hrs for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sum of Pain Intensity Difference Over 48 Hours (SPID48)Time frame: 48 hours

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Glendale, California

  • Site not named

    Pasadena, Maryland

  • Site not named

    Austin, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    San Marcos, Texas

  • Site not named

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.